Viral safety studies of Flebogamma®, a pasteurized liquid intravenous immunoglobulin.

被引：0
|
作者：
Biescas, H [1 ]
Ruiz, P [1 ]
Gajardo, R [1 ]
Massot, M [1 ]
Ristol, P [1 ]
Jorquera, JI [1 ]
机构：
[1] Inst Grifols SA, Res & Dev Area, Barcelona, Spain
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4018
引用
收藏
页码：134B / 134B
页数：1
相关论文
共 50 条
  • [21] PREPARATION OF PASTEURIZED LIQUID INTRAVENOUS IMMUNOGLOBULIN G (IVIG) WITHOUT USING CHROMATOGRAPHY METHOD
    Aghaie, A.
    VOX SANGUINIS, 2010, 99 : 234 - 234
  • [22] Viral safety of intravenous immunoglobulin: The view of the French Medicine Agency
    Rossi, F
    INTRAVENOUS IMMUNOGLOBULIN: RESEARCH AND THERAPY, 1996, : 19 - 23
  • [23] Inactivation and elimination of model viruses during the production of intravenous immunoglobulin.
    Kempf, C
    Siegenthaler, A
    Omar, A
    BLOOD, 1995, 86 (10) : 858 - 858
  • [24] Effective treatment of inclusion body myositis using intravenous immunoglobulin.
    Mukunda, BN
    Kumar, PD
    Smith, HR
    JOURNAL OF INVESTIGATIVE MEDICINE, 2000, 48 (02) : 198A - 198A
  • [25] Multifocal motor neuropathy. Immediate response to intravenous immunoglobulin.
    Cammarota, A
    Nogues, M
    Rivero, A
    Garcia, H
    MEDICINA-BUENOS AIRES, 2001, 61 (04) : 441 - 444
  • [26] Efficacy, Pharmacokinetics, Safety, and Tolerability of Flebogamma® 10% DIF, a High-Purity Human Intravenous Immunoglobulin, in Primary Immunodeficiency
    Melvin Berger
    Paul J. Pinciaro
    Arthur Althaus
    Mark Ballow
    Akhilesh Chouksey
    James Moy
    Hans Ochs
    Mark Stein
    Journal of Clinical Immunology, 2010, 30 : 321 - 329
  • [27] Remission of vitiligo during treatment with intravenous immunoglobulin. Report of one case
    Badilla P., Alejandro
    Diaz G., Carolina
    REVISTA MEDICA DE CHILE, 2011, 139 (04) : 484 - 488
  • [28] A Monoclonal Antibody Which Possibly May Replace the Therapeutic Intravenous Immunoglobulin.
    Ravindranath, M.
    Terasaki, P.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 477 - 477
  • [29] Flebogamma® 5% DIF development: rationale for a new option in intravenous immunoglobulin therapy
    Jorquera, J. I.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2009, 157 : 17 - 21
  • [30] Flebogamma® 5 % DIF Intravenous Immunoglobulin for Replacement Therapy in Children with Primary Immunodeficiency Diseases
    Mark Ballow
    Paul J. Pinciaro
    Timothy Craig
    Gary Kleiner
    James Moy
    Hans D. Ochs
    John Sleasman
    William Smits
    Journal of Clinical Immunology, 2016, 36 : 583 - 589
12345